Friday 6 November 2026
Export GKOS’s income statement to Excel — free account
Glaukos Corporation
GKOS Healthcare Medical Devices
Glaukos Corporation’s revenue for fiscal 2025 (year ended December 2025) was $507.4 million, up 32.3% from fiscal 2024.
- Revenue
- +58.0%
- EPS
- +110.7%
- Free cash flow
- +411.2%
- Total debt
- −2.25%
Quarter to September 2026, against a year earlier
224.21
4.23
+1.92%
Follow GKOS
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
14.06 | 13.41 | 11.33 | 12.73 | |
P/FCF ratio |
269.42 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
251.61 | 554.57 | (498.69) | 943.64 | |
P/B ratio |
13.53 | 12.04 | 9.31 | 9.84 | |
Price to Tangible BV |
18.33 | 16.82 | 13.26 | 14.43 | |
EV/Sales |
14.07 | 13.51 | 11.46 | 12.86 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
203.61 | (8,716.70) | (718.34) | (441.27) | |
EV/FCF |
269.68 | (678.98) | (180.03) | (167.07) | |
Quick Ratio |
3.84 | 4.15 | 4.43 | 3.82 | |
Current Ratio |
4.57 | 5.04 | 5.43 | 4.69 | |
Net Debt/EBITDA |
(25.55) | 30.16 | 29.18 | 1.66 | |
Debt/Assets |
6.83% | 7.32% | 7.58% | 7.62% | |
Debt/Equity |
0.09 | 0.10 | 0.10 | 0.10 | |
Asset Turnover |
0.70 | 0.64 | 0.59 | 0.54 | |
Operating CF/Net income |
19.11 | (0.81) | 0.63 | (0.05) | |
Capex/Depreciation |
(0.21) | (0.27) | (0.31) | (0.23) | |
Interest Coverage |
0.76 | (11.83) | (17.65) | (122.05) | |
Research and Development Expense of Revenue |
22.79% | 28.45% | 29.32% | 30.50% | |
Selling, General and Administrative Expense of Revenue |
62.05% | 62.53% | 61.73% | 66.17% | |
Intangible Assets out of Total Assets |
0.19 | 0.21 | 0.22 | 0.23 | |
Share Based Compensation of Revenue |
8.42% | 15.55% | 12.71% | 12.09% | |
Graham Net Nets |
0.03 | 0.03 | 0.04 | 0.04 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(1.79%) | (2.33%) | (3.05%) | (2.89%) | |
Free Cash Flow Yield |
0.37% | (0.15%) | (0.56%) | (0.60%) | |
Revenue per Share |
3.57 | 3.16 | 2.60 | 2.50 | |
Operating CF per Share |
0.65 | 0.25 | (0.22) | 0.12 | |
Capex per Share |
(0.04) | (0.05) | (0.07) | (0.05) | |
Free Cash Flow per Share |
0.62 | 0.21 | (0.28) | 0.07 | |
Cash per Share |
5.70 | 4.87 | 4.77 | 4.87 | |
Shareholders Equity per Share |
12.14 | 11.60 | 11.56 | 11.47 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
12.14 | 11.60 | 11.56 | 11.47 | |
Free Cash Flow |
36.49 | 12.09 | (16.48) | 3.93 | |
Working Capital |
452.92 | 413.45 | 396.34 | 373.71 | |
Capital Expenditures |
(2.08) | (2.74) | (3.96) | (2.91) | |
Net Current Asset Value |
317.40 | 277.74 | 263.36 | 237.65 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.01 | 0.03 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
124.34 | 110.94 | 95.61 | 84.68 | |
Average Payables |
22.15 | 16.41 | 17.49 | 18.83 | |
Average Inventory |
62.45 | 61.96 | 60.92 | 60.62 | |
Average Assets |
989.45 | 953.74 | 929.75 | 934.12 | |
Average Common Equity |
743.41 | 723.80 | 717.44 | 711.54 |
Columns are period end dates · fundamentals updated 5 Nov 2026